File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A pharmacoepidemiologic study of factors influencing the outcome of treatment with lamotrigine in chronic epilepsy

TitleA pharmacoepidemiologic study of factors influencing the outcome of treatment with lamotrigine in chronic epilepsy
Authors
KeywordsChronic epilepsy
Lamotrigine
Pharmacoepidemiology
Seizure free-Retention rate
Issue Date2001
PublisherWiley-Blackwell Publishing, Inc.. The Journal's web site is located at http://www.epilepsia.com/
Citation
Epilepsia, 2001, v. 42 n. 10, p. 1354-1358 How to Cite?
AbstractPurpose: To identify prognostic factors for freedom from seizures and long-term retention of treatment in patients receiving lamotrigine (LTG). Methods: A multicenter, retrospective, case record study of 1,050 patients with chronic epilepsy was carried out. Logistic regression and Cox regression analyses were used to identify clinical features associated with freedom from seizures and retention of treatment, respectively. Long-term retention rates of LTG therapy were estimated using Kaplan-Meier survival analysis. Results: The 1,050 patients with chronic epilepsy were included in the study. Patients with generalized epilepsy (p = 0.01), who were not receiving carbamazepine (CBZ; p = 0.02) were more likely to become seizure-free. Sixty percent of patients continued on LTG therapy >1 year and estimated retention at 8 years was 38%. Patients with generalized epilepsy (p = 0.002), patients receiving concurrent sodium valproate (VPA; p < 0.0001), those not previously exposed to gabapentin and vigabatrin (p < 0.0001), and those in whom the starting dose was lower (p < 0.0012), were more likely to remain on long-term treatment with LTG. The relationships with exposure to other antiepileptic drugs remained significant in patients with focal and with generalized epilepsy when considered separately. Conclusions: The best results from LTG treatment in terms of freedom from seizures and long-term retention of treatment were obtained in patients with generalized epilepsy. Retention of treatment was enhanced by VPA not only in generalized but also in focal epilepsy. The importance of a low starting dose of LTG was again confirmed. The apparent negative effect of CBZ in patients taking LTG merits further investigation.
Persistent Identifierhttp://hdl.handle.net/10722/132909
ISSN
2015 Impact Factor: 4.706
2015 SCImago Journal Rankings: 2.579
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, ICKen_HK
dc.contributor.authorMawer, GEen_HK
dc.contributor.authorSander, JWASen_HK
dc.contributor.authorLhatoo, SDen_HK
dc.date.accessioned2011-04-04T07:57:55Z-
dc.date.available2011-04-04T07:57:55Z-
dc.date.issued2001en_HK
dc.identifier.citationEpilepsia, 2001, v. 42 n. 10, p. 1354-1358en_HK
dc.identifier.issn0013-9580en_HK
dc.identifier.urihttp://hdl.handle.net/10722/132909-
dc.description.abstractPurpose: To identify prognostic factors for freedom from seizures and long-term retention of treatment in patients receiving lamotrigine (LTG). Methods: A multicenter, retrospective, case record study of 1,050 patients with chronic epilepsy was carried out. Logistic regression and Cox regression analyses were used to identify clinical features associated with freedom from seizures and retention of treatment, respectively. Long-term retention rates of LTG therapy were estimated using Kaplan-Meier survival analysis. Results: The 1,050 patients with chronic epilepsy were included in the study. Patients with generalized epilepsy (p = 0.01), who were not receiving carbamazepine (CBZ; p = 0.02) were more likely to become seizure-free. Sixty percent of patients continued on LTG therapy >1 year and estimated retention at 8 years was 38%. Patients with generalized epilepsy (p = 0.002), patients receiving concurrent sodium valproate (VPA; p < 0.0001), those not previously exposed to gabapentin and vigabatrin (p < 0.0001), and those in whom the starting dose was lower (p < 0.0012), were more likely to remain on long-term treatment with LTG. The relationships with exposure to other antiepileptic drugs remained significant in patients with focal and with generalized epilepsy when considered separately. Conclusions: The best results from LTG treatment in terms of freedom from seizures and long-term retention of treatment were obtained in patients with generalized epilepsy. Retention of treatment was enhanced by VPA not only in generalized but also in focal epilepsy. The importance of a low starting dose of LTG was again confirmed. The apparent negative effect of CBZ in patients taking LTG merits further investigation.en_HK
dc.languageengen_US
dc.publisherWiley-Blackwell Publishing, Inc.. The Journal's web site is located at http://www.epilepsia.com/en_HK
dc.relation.ispartofEpilepsiaen_HK
dc.subjectChronic epilepsyen_HK
dc.subjectLamotrigineen_HK
dc.subjectPharmacoepidemiologyen_HK
dc.subjectSeizure free-Retention rateen_HK
dc.titleA pharmacoepidemiologic study of factors influencing the outcome of treatment with lamotrigine in chronic epilepsyen_HK
dc.typeArticleen_HK
dc.identifier.emailWong, ICK: wongick@hku.hken_HK
dc.identifier.authorityWong, ICK=rp01480en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1046/j.1528-1157.2001.02101.xen_HK
dc.identifier.pmid11737172-
dc.identifier.scopuseid_2-s2.0-0035160490en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0035160490&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume42en_HK
dc.identifier.issue10en_HK
dc.identifier.spage1354en_HK
dc.identifier.epage1358en_HK
dc.identifier.isiWOS:000172272400018-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridWong, ICK=7102513915en_HK
dc.identifier.scopusauthoridMawer, GE=7004053826en_HK
dc.identifier.scopusauthoridSander, JWAS=7202898360en_HK
dc.identifier.scopusauthoridLhatoo, SD=35482407900en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats